Molnupiravir is a type of antiviral medication specifically developed to combat COVID-19. It works by interfering with the replication process of the virus, effectively stopping it from spreading further within the body. This medication has shown promise in reducing the severity of illness and shortening the duration of symptoms during clinical trials.
What makes molnupiravir particularly noteworthy is its potential for at-home use, which could potentially lessen the strain on healthcare systems. However, as with any medication, it is important to consult with healthcare professionals before use to ensure its appropriateness and to be aware of any potential side effects.
| CAS | 2349386-89-4 |
| Country Of Origin | China |
| Manufacturer | LongilatBio |
| Molecular Formula | C13H19N3O7 |
| Indication | Treatment Of COVID-19 |
| Generic Name | EIDD-2801 |
| Shipping Method | Air(UPS, FedEx, TNT, EMS) Or Sea |
| Purity | 99% |
| COA | Available |
Molnupiravir is an antiviral medication that was originally developed to treat influenza. It works by inhibiting the replication of RNA viruses, which are responsible for many viral infections. Its mechanism of action involves introducing errors into the viral genetic material, making it non-functional or less infectious. This disruption of viral replication is effective in suppressing viral spread within the body, ultimately reducing the severity of infection and aiding in the recovery process.
This antiviral property of molnupiravir has potential implications for its usage in treating Feline Infectious Peritonitis (FIP). FIP is a viral disease caused by certain strains of feline coronavirus and is considered challenging to treat with limited treatment options available. Unfortunately, FIP often proves fatal in affected cats.
As FIP is caused by a coronavirus, which is an RNA virus, molnupiravir's mechanism of action targeting RNA viruses may effectively inhibit the replication of the feline coronavirus responsible for this disease. This could potentially reduce the severity of FIP and improve the chances of recovery in affected cats.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
